Ran Zheng
Director/Board Member at CARIBOU BIOSCIENCES, INC.
Net worth: - $ as of 2024-04-29
Ran Zheng active positions
| Companies | Position | Start | End |
|---|---|---|---|
| CARIBOU BIOSCIENCES, INC. | Director/Board Member | 2021-09-23 | - |
| Independent Dir/Board Member | 2021-09-23 | - | |
| Landmark Bio PBLLC | Director/Board Member | 2021-02-28 | - |
| Chief Executive Officer | 2021-02-28 | - |
Career history of Ran Zheng
Former positions of Ran Zheng
| Companies | Position | Start | End |
|---|---|---|---|
| ORCHARD THERAPEUTICS PLC | Chief Tech/Sci/R&D Officer | 2019-03-17 | 2021-01-31 |
| AMGEN INC. | Corporate Officer/Principal | - | - |
Training of Ran Zheng
| Beijing Forestry University | Undergraduate Degree |
| University of Minnesota | Graduate Degree |
Statistics
International
| United States | 5 |
| United Kingdom | 2 |
| China | 2 |
Operational
| Director/Board Member | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| AMGEN INC. | Health Technology |
| CARIBOU BIOSCIENCES, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
| Landmark Bio PBLLC |
- Stock Market
- Insiders
- Ran Zheng
- Experience
